ADC Therapeutics Phase II ZYNLONTA Results Demonstrated Durable, Long-Term Responses in Relapsed/Refractory DLBCL

June 9, 2023

(24/7 MARKET NEWS) – ADC Therapeutics SA (NYSE:ADCT) reported, this morning, that it will present updated results data, from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in a poster at the European Hematology Association 2023 Hybrid Congress (EHA2023) and will also be featured in an oral presentation at the 17th International Conference on Malignant Lymphoma (17-ICML) being held in Lugano, Switzerland from June 13-17, 2023.

ADC Therapeutics is trading at $2.60 +0.10 (+4.00%), on 176.3K premarket shares traded.

Its 52-week range is $1.85 to $10.88. Its next key inflection point is $2.75. It’s doubtful that it breaks through that on strong trading volume in this market, but if it does it could open the door to a big run higher.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.